SCHEMBL4052840

SCHEMBL4052840

Cc1oc(-c2ccccc2)nc1COc1ccc(CON=C(CCCCCCC(=O)O)c2ccccc2)cc1

nearest known ligand 0.88

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
PPARG P37231 16/20 0.88
PPARA Q07869 14/20 0.88
FFAR1 O14842 1/20 0.66
PPARD Q03181 1/20 0.50
MAPT P10636 1/20 0.48
KDR P35968 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7835387 1.00 PPARG (0.88) PPARGPPARAFFAR1PPARDMAPT
SCHEMBL6157410 1.00 PPARG (0.88) PPARGPPARAFFAR1PPARDMAPT
SCHEMBL4052836 1.00 PPARG (0.88) PPARGPPARAFFAR1PPARDMAPT
SCHEMBL6157324 1.00 PPARG (0.88) PPARGPPARAFFAR1PPARDMAPT
SCHEMBL6158990 1.00 PPARG (0.88) PPARGPPARAFFAR1PPARDMAPT
SCHEMBL6157328 1.00 PPARG (0.88) PPARGPPARAFFAR1PPARDMAPT
SCHEMBL6158923 1.00 PPARG (0.88) PPARGPPARAFFAR1PPARDMAPT
SCHEMBL6160415 0.99 PPARG (0.90) PPARGPPARAFFAR1PPARDMAPT
SCHEMBL6158370 0.99 PPARG (0.90) PPARGPPARAFFAR1PPARDMAPT
SCHEMBL6158379 0.99 PPARG (0.90) PPARGPPARAFFAR1PPARDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1428531-A1 Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2004-06-16 EP claimed
US-6677363-B1 ADMINISTERING PIOGLITAZONE OR SALT, OXIME INSULIN SENSITIZER, FK-614, KRP-297, AND 5-((6-(2-FLUOROBENZYLOXY)-2-NAPHTHYL)METHYL)-2,4-THIAZOLIDINEDIONE TO TREAT DIABETES TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2004-01-13 US claimed
US-20030186985-A1 Oxyiminoalkanoic acid derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-10-02 US claimed
US-6518435-B1 Production method, a method of producing a compound represented by the formula (III) production method of oxyimino- alkanoic acid derivatives having an anti-diabetic activity. TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-02-11 US claimed
EP-1227081-A1 PROCESS FOR THE PREPARATION OF OXYIMINOALKANOIC ACID DERIVATIVES Takeda Chemical Industries, Ltd. (JP) 2002-07-31 EP claimed
US-6251926-B1 OXYIMINOALKANOIC ACID DERIVATIVES HAVING HYPOGLYCEMIC EFFECT AND HYPOLIPIDEMIC EFFECT, IS USEFUL FOR TREATMENT OF DIABETES MELLITUS, HYPERLIPEMIA, IMPAIRED GLUCOSE TOLERANCE INFLAMMATORY DISEASE AND ARTERIOSCLEROSIS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-06-26 US claimed
EP-1077957-A1 OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY Takeda Chemical Industries, Ltd. (JP) 2001-02-28 EP claimed
WO-1999058510-A1 OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1999-11-18 WO claimed
US-7595333-B2 Agent for improving acidosis TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-29 US disclosed
US-20050239854-A1 Body weight gain inhibitors SUGIYAMA YASUO 2005-10-27 US disclosed
US-6924300-B2 Oxyiminoalkanoic acid derivatives TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-08-02 US disclosed
EP-1077957-B1 OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2004-08-04 EP disclosed
EP-1428531-A1 Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2004-06-16 EP disclosed
US-20040106649-A1 Agent for improving acidosis TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-06-03 US disclosed
EP-1169037-A2 USE OF INSULIN SENSITISERS FOR IMPROVING KETOSIS Takeda Pharmaceutical Company Limited (JP) 2002-01-09 EP disclosed
US-6251926-B1 OXYIMINOALKANOIC ACID DERIVATIVES HAVING HYPOGLYCEMIC EFFECT AND HYPOLIPIDEMIC EFFECT, IS USEFUL FOR TREATMENT OF DIABETES MELLITUS, HYPERLIPEMIA, IMPAIRED GLUCOSE TOLERANCE INFLAMMATORY DISEASE AND ARTERIOSCLEROSIS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-06-26 US disclosed
EP-1077957-A1 OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY Takeda Chemical Industries, Ltd. (JP) 2001-02-28 EP disclosed
WO-2000061127-A2 USE OF INSULIN SENSITISERS FOR IMPROVING KETOSIS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2000-10-19 WO disclosed
JP-2000198772-A OXYIMINOALKANOIC ACID DERIVATIVE TAKEDA CHEM IND LTD 2000-07-18 JP disclosed
WO-1999058510-A1 OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1999-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186985-A1 Oxyiminoalkanoic acid derivatives GPR119, IRS1, CPT1A PPARG 401/4885PPARA 152/4885FFAR1 53/4885
US-20050239854-A1 Body weight gain inhibitors PPARG, GPR119, PPARA PPARG 1/4885PPARA 3/4885FFAR1 43/4885
US-20040106649-A1 Agent for improving acidosis GPR119, SLC2A8, SLC2A1 PPARG 422/4885PPARA 326/4885FFAR1 77/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.